Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Quick Healing Bone Scaffold Could Be a Game-Changer in Tissue Regeneration

By HospiMedica International staff writers
Posted on 28 Jun 2023

Bone tissue loss, which can result from trauma, osteoporosis, and metastatic bone diseases, impacts 20 million individuals globally every year, making bone the second most frequently transplanted tissue. More...

Established techniques such as autografting, allografting, and xenografting are commonly used, yet they pose challenges like infection risk and rejection that impede their clinical applications. Bone tissue engineering, a method that combines scaffolds, hydrogels, and occasionally stem cells to create bone tissue, is a potential solution. Despite its potential, the technique still hasn't reached its full capabilities, mainly due to the lack of biomaterial systems that accurately replicate native bone complexity.

Now, researchers at Technical University of Denmark (DTU, Kongens Lyngby, Denmark) have advanced tissue regeneration by developing a multi-leveled scaffold that replicates the properties of native bone on nano, micro, and macro scales. In their study, they observed near-complete bone healing in a rat model within eight weeks using their scaffold, without the need for growth factors. Additionally, the scaffold is combinatorial, capable of releasing several essential bone minerals while meeting the mechanical properties required to match the compressive strength of human cancellous bone. The team is now aiming to reduce the healing time to four weeks and achieve near-immediate tissue regeneration without using endocrine factors and cells and is also investigating potential applications for other tissues.

This research has huge implications. By incorporating stem cells, bioactive components like collagen and gelatin, coatings that encourage native cell migration into the scaffolds, and electromagnetic stimulation, this could potentially accelerate the healing process for soldiers with severe musculoskeletal fractures or civilians with traumatic injuries. These individuals typically face months of hospitalization and a lengthy recovery. Notably, the newly developed scaffold is primarily composed of glass, alginate, and nano silicate, materials already approved by the FDA. This approval significantly reduces regulatory obstacles, allowing the scaffold to be confidently and efficiently used in clinical settings, thereby expediting development and improving patient outcomes.

"I believe this discovery could be a game-changer in the field of tissue regeneration, and I hope to see this technology being used to help those in need," said Associate Professor Alireza Dolatshahi-Pirouz who led the research team at DTU Health Tech.

Related Links:
Technical University of Denmark


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.